Cite
HARVARD Citation
Bendell, J. et al. (2015). A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma. Cancer. 121 (19), pp. 3481-3490. [Online].